Cargando…

TSPO imaging using the novel PET ligand [(18)F]GE-180: quantification approaches in patients with multiple sclerosis

BACKGROUND: PET ligands targeting the translocator protein (TSPO) represent promising tools to visualise neuroinflammation. Here, we analysed parameters obtained in dynamic and static PET images using the novel TSPO ligand [(18)F]GE-180 in patients with relapsing remitting multiple sclerosis (RRMS)...

Descripción completa

Detalles Bibliográficos
Autores principales: Vomacka, Lena, Albert, Nathalie Lisa, Lindner, Simon, Unterrainer, Marcus, Mahler, Christoph, Brendel, Matthias, Ermoschkin, Larissa, Gosewisch, Astrid, Brunegraf, Anika, Buckley, Christopher, Kümpfel, Tania, Rupprecht, Rainer, Ziegler, Sibylle, Kerschensteiner, Martin, Bartenstein, Peter, Böning, Guido
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5693838/
https://www.ncbi.nlm.nih.gov/pubmed/29150726
http://dx.doi.org/10.1186/s13550-017-0340-x
_version_ 1783279995777449984
author Vomacka, Lena
Albert, Nathalie Lisa
Lindner, Simon
Unterrainer, Marcus
Mahler, Christoph
Brendel, Matthias
Ermoschkin, Larissa
Gosewisch, Astrid
Brunegraf, Anika
Buckley, Christopher
Kümpfel, Tania
Rupprecht, Rainer
Ziegler, Sibylle
Kerschensteiner, Martin
Bartenstein, Peter
Böning, Guido
author_facet Vomacka, Lena
Albert, Nathalie Lisa
Lindner, Simon
Unterrainer, Marcus
Mahler, Christoph
Brendel, Matthias
Ermoschkin, Larissa
Gosewisch, Astrid
Brunegraf, Anika
Buckley, Christopher
Kümpfel, Tania
Rupprecht, Rainer
Ziegler, Sibylle
Kerschensteiner, Martin
Bartenstein, Peter
Böning, Guido
author_sort Vomacka, Lena
collection PubMed
description BACKGROUND: PET ligands targeting the translocator protein (TSPO) represent promising tools to visualise neuroinflammation. Here, we analysed parameters obtained in dynamic and static PET images using the novel TSPO ligand [(18)F]GE-180 in patients with relapsing remitting multiple sclerosis (RRMS) and an approach for semi-quantitative assessment of this disease in clinical routine. Seventeen dynamic [(18)F]GE-180 PET scans of RRMS patients were evaluated (90 min). A pseudo-reference region (PRR) was defined after identification of the least disease-affected brain area by voxel-based comparison with six healthy controls (HC) and upon exclusion of voxels suspected of being affected in static 60–90 min p.i. images. Standardised uptake value ratios (SUVR) obtained from static images normalised to PRR were correlated to the distribution volume ratios (DVR) derived from dynamic data with Logan reference tissue model. RESULTS: Group comparison with HC revealed white matter and thalamus as most affected regions. Fewest differences were found in grey matter, and normalisation to frontal cortex (FC) yielded the greatest reduction in variability of healthy grey and white matter. Hence, FC corrected for affected voxels was chosen as PRR, leading to time-activity curves of FC which were congruent to HC data (SUV(60–90) 0.37, U test P = 0.42). SUVR showed a very strong correlation with DVR (Pearson ρ > 0.9). Focal MS lesions exhibited a high SUVR (range, 1.3–3.2). CONCLUSIONS: This comparison with parameters from dynamic data suggests that SUVR normalised to corrected frontal cortex as PRR is suitable for the quantification of [(18)F]GE-180 uptake in lesions and different brain regions of RRMS patients. This efficient diagnostic protocol based on static [(18)F]GE-180 PET scans acquired 60–90 min p.i. allows the semi-quantitative assessment of neuroinflammation in RRMS patients in clinical routine.
format Online
Article
Text
id pubmed-5693838
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-56938382017-12-01 TSPO imaging using the novel PET ligand [(18)F]GE-180: quantification approaches in patients with multiple sclerosis Vomacka, Lena Albert, Nathalie Lisa Lindner, Simon Unterrainer, Marcus Mahler, Christoph Brendel, Matthias Ermoschkin, Larissa Gosewisch, Astrid Brunegraf, Anika Buckley, Christopher Kümpfel, Tania Rupprecht, Rainer Ziegler, Sibylle Kerschensteiner, Martin Bartenstein, Peter Böning, Guido EJNMMI Res Original Research BACKGROUND: PET ligands targeting the translocator protein (TSPO) represent promising tools to visualise neuroinflammation. Here, we analysed parameters obtained in dynamic and static PET images using the novel TSPO ligand [(18)F]GE-180 in patients with relapsing remitting multiple sclerosis (RRMS) and an approach for semi-quantitative assessment of this disease in clinical routine. Seventeen dynamic [(18)F]GE-180 PET scans of RRMS patients were evaluated (90 min). A pseudo-reference region (PRR) was defined after identification of the least disease-affected brain area by voxel-based comparison with six healthy controls (HC) and upon exclusion of voxels suspected of being affected in static 60–90 min p.i. images. Standardised uptake value ratios (SUVR) obtained from static images normalised to PRR were correlated to the distribution volume ratios (DVR) derived from dynamic data with Logan reference tissue model. RESULTS: Group comparison with HC revealed white matter and thalamus as most affected regions. Fewest differences were found in grey matter, and normalisation to frontal cortex (FC) yielded the greatest reduction in variability of healthy grey and white matter. Hence, FC corrected for affected voxels was chosen as PRR, leading to time-activity curves of FC which were congruent to HC data (SUV(60–90) 0.37, U test P = 0.42). SUVR showed a very strong correlation with DVR (Pearson ρ > 0.9). Focal MS lesions exhibited a high SUVR (range, 1.3–3.2). CONCLUSIONS: This comparison with parameters from dynamic data suggests that SUVR normalised to corrected frontal cortex as PRR is suitable for the quantification of [(18)F]GE-180 uptake in lesions and different brain regions of RRMS patients. This efficient diagnostic protocol based on static [(18)F]GE-180 PET scans acquired 60–90 min p.i. allows the semi-quantitative assessment of neuroinflammation in RRMS patients in clinical routine. Springer Berlin Heidelberg 2017-10-26 /pmc/articles/PMC5693838/ /pubmed/29150726 http://dx.doi.org/10.1186/s13550-017-0340-x Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Research
Vomacka, Lena
Albert, Nathalie Lisa
Lindner, Simon
Unterrainer, Marcus
Mahler, Christoph
Brendel, Matthias
Ermoschkin, Larissa
Gosewisch, Astrid
Brunegraf, Anika
Buckley, Christopher
Kümpfel, Tania
Rupprecht, Rainer
Ziegler, Sibylle
Kerschensteiner, Martin
Bartenstein, Peter
Böning, Guido
TSPO imaging using the novel PET ligand [(18)F]GE-180: quantification approaches in patients with multiple sclerosis
title TSPO imaging using the novel PET ligand [(18)F]GE-180: quantification approaches in patients with multiple sclerosis
title_full TSPO imaging using the novel PET ligand [(18)F]GE-180: quantification approaches in patients with multiple sclerosis
title_fullStr TSPO imaging using the novel PET ligand [(18)F]GE-180: quantification approaches in patients with multiple sclerosis
title_full_unstemmed TSPO imaging using the novel PET ligand [(18)F]GE-180: quantification approaches in patients with multiple sclerosis
title_short TSPO imaging using the novel PET ligand [(18)F]GE-180: quantification approaches in patients with multiple sclerosis
title_sort tspo imaging using the novel pet ligand [(18)f]ge-180: quantification approaches in patients with multiple sclerosis
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5693838/
https://www.ncbi.nlm.nih.gov/pubmed/29150726
http://dx.doi.org/10.1186/s13550-017-0340-x
work_keys_str_mv AT vomackalena tspoimagingusingthenovelpetligand18fge180quantificationapproachesinpatientswithmultiplesclerosis
AT albertnathalielisa tspoimagingusingthenovelpetligand18fge180quantificationapproachesinpatientswithmultiplesclerosis
AT lindnersimon tspoimagingusingthenovelpetligand18fge180quantificationapproachesinpatientswithmultiplesclerosis
AT unterrainermarcus tspoimagingusingthenovelpetligand18fge180quantificationapproachesinpatientswithmultiplesclerosis
AT mahlerchristoph tspoimagingusingthenovelpetligand18fge180quantificationapproachesinpatientswithmultiplesclerosis
AT brendelmatthias tspoimagingusingthenovelpetligand18fge180quantificationapproachesinpatientswithmultiplesclerosis
AT ermoschkinlarissa tspoimagingusingthenovelpetligand18fge180quantificationapproachesinpatientswithmultiplesclerosis
AT gosewischastrid tspoimagingusingthenovelpetligand18fge180quantificationapproachesinpatientswithmultiplesclerosis
AT brunegrafanika tspoimagingusingthenovelpetligand18fge180quantificationapproachesinpatientswithmultiplesclerosis
AT buckleychristopher tspoimagingusingthenovelpetligand18fge180quantificationapproachesinpatientswithmultiplesclerosis
AT kumpfeltania tspoimagingusingthenovelpetligand18fge180quantificationapproachesinpatientswithmultiplesclerosis
AT rupprechtrainer tspoimagingusingthenovelpetligand18fge180quantificationapproachesinpatientswithmultiplesclerosis
AT zieglersibylle tspoimagingusingthenovelpetligand18fge180quantificationapproachesinpatientswithmultiplesclerosis
AT kerschensteinermartin tspoimagingusingthenovelpetligand18fge180quantificationapproachesinpatientswithmultiplesclerosis
AT bartensteinpeter tspoimagingusingthenovelpetligand18fge180quantificationapproachesinpatientswithmultiplesclerosis
AT boningguido tspoimagingusingthenovelpetligand18fge180quantificationapproachesinpatientswithmultiplesclerosis